Working with biopharma to unleash the power of RWE

Solutions designed to reduce risk, increase value, and accelerate the delivery of safe and effective treatments

Empowering decision makers in biopharma at every phase of the lifecycle, from clinical development to post-market assessment.

Research & Development

Optimize clinical development, prove safety and effectiveness
Research & Development solutions

Treatment & Disease Landscape

Product Label Evidence Creation

TPP & Trial Optimization

Safety Evaluation & Monitoring

Data Amplification & Augmentation
To help you
- Accelerate time to market
- Rapidly address regulatory requests
- Reduce risk and increase probability of trial success
- Lower costs
- Inform more robust labeling
HEOR & Market Access

Demonstrate asset value
HEOR & Market Access solutions

Payer/HTA Value Demonstration

Payer Engagement

Treatment & Disease Landscape

Access Optimization

Rare Disease Value Support
To help you
- Increase productivity of stat and HEOR teams
- Free up time to focus on innovative analysis vs. programming
- Accelerate speed to answer
- Improve coverage
Enterprise-wide

Streamline evidence across assets and portfolios
Enterprise-wide solutions

RWE Management

RWD Identification & Access

Strategic Partnerships

Synthetic Data Generation & Access

Data Privacy Risk Assessment & Remediation
To help you
- Increase speed, scalability and quality of RWE generation
- Ensure transparent and auditable evidence generation
- Support build out and management of RWE CoE

Generating scientifically valid RWE presented in a way regulatory agencies and HTAs trust

FDA selected Aetion

to use real-world evidence to study COVID-19 interventions and advance regulatory science and innovation.

EMA selected Aetion

to help measure the utilization, safety, and efficacy of medicines used across Europe.

“We believe that strategic partnerships will advance our capabilities for rapid analytics. The Aetion Evidence Platform has helped reduce the completion time for UCB’s RWE initiatives by 50% and has enhanced our capabilities to run multiple concurrent studies.”

— Dr. Eddie Lee

Head, US HEOR Strategy, UCB

“Aetion is a leader in turning real-world data into RWE to inform critical decision-making across product development, reimbursement, and commercialization. Our partnership will accelerate our late-stage clinical programs and bring our therapy to the millions of patients living with MCI and Alzheimer’s disease, where safer options are still needed.“

— Brent Vaughan, CEO

Cognito Therapeutics